Who is sponsoring NCT00579969?

NCT00579969 is sponsored by University of Nebraska.

What drugs are being tested in NCT00579969?

Interventions: Latanoprost, Timolol.

What is the status of NCT00579969?

NCT00579969 is currently TERMINATED.

Last reviewed 2023-12-20 · How we verify

Comparison of the Effects of Latanoprost and Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients

NCT00579969 Phase 2 TERMINATED

The primary purpose of this study is to show, through a controlled masked clinical study of subjects with ocular hypertension (OHT), that latanoprost increases the low uveoscleral drainage of aqueous humor back to normal levels, and timolol maleate reduces the formation of aqueous humor below normal. Both of these mechanisms will effectively reduce intraocular pressure (IOP). The secondary purpose is to assess the effects of both latanoprost and timolol maleate on the fluorophotometric outflow facility, and episcleral venous pressure and on all parameters over time.

Details

Lead sponsor	University of Nebraska
Phase	Phase 2
Status	TERMINATED
Enrolment	30
Start date	2003-12
Completion	2008-10

Conditions

Glaucoma

Interventions

Latanoprost
Timolol

Primary outcomes

Comparison of Latanoprost and Timolol in lowering ocular pressure — 6 months
Two drugs, Latanoprost and Timolol, will be compared in ocular hypertensive patients in their ability to lower ocular pressure at six months using a Goldmann applanation tonometer (GAT).

Countries

United States